FRAMINGHAM, Mass. and SYDNEY, Sept 23, 2010 /PRNewswire via COMTEX/ --
HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Lazard Capital Markets Second Annual Circulatory Assist Device Day from 2:00-3:00 pm EDT on Wednesday, September 29. The conference will be held at the Pierre Hotel in New York City.
For parties interested in listening to the event, a conference call will be available beginning at 2:00 pm EDT. The teleconference can be accessed by calling (888) 299-7209 or (719) 325-4856, passcode: 3447088. Please dial in 10-15 minutes prior to the beginning of the call. A replay of the conference call will be available through Sunday, October 3, at (888) 203-1112 or (719) 457-0820, passcode: 3447088.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare(R) Ventricular Assist System features the HVAD(R) pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union. The device is currently the subject of United States clinical trials for two indications: destination therapy and bridge-to-transplant under a continued access protocol. For additional information, please visit the company's website at www.heartware.com.
HeartWare International, Inc. is a member of the Russell 2000(R) and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.
For further information:
HeartWare International, Inc.
Phone: +1 508 739 0864
SOURCE HeartWare International, Inc.